Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A heart drug by French pharmaceutical giant Sanofi-Aventis has been linked to liver damage in some patients, two of whom had to receive transplants, the US Food and Drug Administration said Friday.
Dronedarone, marketed as Multaq, was approved in 2009 and has been prescribed at least 492,000 times to people in the United States for treating abnormal heart rhythm.
The FDA issued its warning to the public and to health professionals, saying labels to the medication would be changed to advise of possible liver dangers.
People taking the drug should call their doctor if they experience symptoms such as itching, yellow eyes or skin, dark urine, loss of appetite, or light-colored stools, the FDA said.
Two elderly women were found to have severe liver failure four and a half and six months after they began taking the drug, the FDA said.
Both had to have their livers removed and doctors could find no other reason why they would have sustained that degree of damage, the FDA said.
The drug is already not supposed to be given to patients who have severe heart failure or have recently been hospitalized for heart failure, the FDA said.
"In a study of patients with these conditions, patients given dronedarone had a greater than two-fold increase in risk of death," the FDA said.
ksh/mac
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments